ArticlePakistan journal of medical sciences2026
Real world lessons on tyrosine kinase inhibitor response and resistance in CML from a developing country Pakistan.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to evaluate treatment responses, resistance and molecular characteristics of CML patients on TKI therapies to identify factors associated with suboptimal outcomes. Methodology: A retrospective observational study was conducted between January 2022 to December 2025 on 209 CML patients recruited at Mayo Hospital Lahore. Patients who achieved DMR and MMR were included. Minimum required duration of DMR was three years. Results: A total of 209 patients; 187 (89.4%) were in chronic phase, 12 (5.7%) in accelerated phase, and 10 (4.7%) in blast crisis. The majority were between 30-50 years of age and commonly observed splenomegaly (81.3%) and hepatomegaly (68.4%). Imatinib was prescribed to 114 patients (54.5%); however, 22 required a switch to nilotinib due to resistance.Among CP-CML, 45 (24.0%) patients achieved deep molecular response (DMR) and 18 (9.6%) attained major molecular response (MMR), while one patient from accelerated phase exhibited MMR, leaving more than two-thirds with incomplete responses despite prolonged therapy.Mutation analysis revealed G250E in a blast-phase patient with fatal outcome; another blast case with nilotinib resistance exhibited E459K and expired, E459K in accelerated-phase patient resistant to nilotinib. JAK2 (V617F) in CP-CML/MPN overlap two cases whereas 10 patients remained negative for JAK2 mutation. Death of five out of 10 blast patients have been confirmed. Conclusions: These real-world findings highlight the effectiveness of TKI therapy to achieving molecular responses, particularly in a substantial percentage of CP patients. However, variability in treatment response and emerging of resistance-associated mutations in advanced phases, emphasize the personalized management strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.